SCHEMBL7120427

SCHEMBL7120427

N#Cc1ccc(S(=O)(=O)Nc2ccc(Br)cc2C(=O)Nc2ccc(Br)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 2/20 0.71
SLC10A2 Q12908 1/20 0.71
SLC10A1 Q14973 1/20 0.71
IDO1 P14902 3/20 0.58
GPR27 Q9NS67 6/20 0.53
AVPR2 P30518 2/20 0.53
KDM1A O60341 2/20 0.53
METAP2 P50579 2/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
SLC6A3 Q01959 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116008 0.91 SLC10A6 (0.85) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7208184 0.85 SLC10A6 (0.76) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7126120 0.85 SLC10A6 (0.98) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7120319 0.84 SLC10A6 (0.76) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL5114790 0.84 SLC10A6 (0.68) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL6756862 0.83 SLC10A6 (1.00) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7213023 0.83 SLC10A6 (0.73) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7209239 0.82 SLC10A6 (0.71) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7128123 0.82 SLC10A6 (0.71) SLC10A6SLC10A2SLC10A1IDO1GPR27
SCHEMBL7213164 0.82 SLC10A6 (0.71) SLC10A6SLC10A2SLC10A1GPR27AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US claimed
CN-1429108-A Phosphate transport inhibitors SMITHKLINE BEECHAM CORP (US) 2003-07-09 CN claimed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP claimed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO claimed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216449-A1 Phosphate transport inhibitors SLC34A2, SLC34A1, SLC34A3 SLC10A6 19/4885SLC10A2 57/4885SLC10A1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.